Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Biogeographical distribution of gut microbiome composition and function is partially recapitulated by fecal transplantation into germ-free mice

Yang JC, Lagishetty V, Aja E, Arias-Jayo N, Chang C, Hauer M, Katzka W, Zhou Y, Sedighian F, Koletic C, Liang F, Dong TS, Situ[...]

Extended flexible sigmoidoscopy using water exchange facilitates a complete colon examination without sedation in participants undergoing average risk colorectal cancer screening: results from a randomized trial

Bak A, Parker B, Perini R, Aulakh A, Oliveira C, Richardson W, Hirschkorn P, Sullivan B, Recsky M, Orlando T, Leung F. Extended flexible sigmoidoscopy[...]

Genome-Wide DNA Methylation Identifies Potential Disease-Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease

Mahurkar-Joshi S, Thompson M, Villarruel E, Lewis JD, Lin LD, Farid M, Nayeb-Hashemi H, Storage T, Weiss GA, Limketkai BN, Sauk JS, Mayer EA, Chang[...]